Loading stock data…
Paysign, Inc. (PAYS)
$12.88-0.57 (-4.24%)
Market ClosedLast close Sep 8
Paysign, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Paysign, Inc. in the Technology sector is trading at $12.88 with a market capitalization of $381M. Wall Street consensus targets $13.10 (5 analysts), implying a +1.7% move over the next 12 months. The stock is currently near its 52-week high of $14.43, remaining 93.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $28.04M↑ | $22.76M↑ | $21.60M↑ | $19.08M↑ | $18.60M |
| Gross Profit | $18.22M↑ | $13.12M↑ | $12.15M↑ | $11.76M↑ | $11.69M |
| Operating Income | $6.67M↑ | $1.85M↑ | $1.58M↑ | $1.44M↓ | $2.49M |
| Net Income | $5.44M↑ | $1.36M↓ | $2.22M↑ | $1.39M↓ | $2.59M |
Peer Comparison
AAPLMSFTGOOGL
Fundamentals
Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the Unite...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$380.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.06
Beta
Defensive asset. Lower volatility than the S&P 500.
0.72
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.91%
Volume
Today's trading volume
1.09M
Recent News
Paysign Targets $117M Revenue as Patient-Affordability Business Surges
Paysign (NASDAQ:PAYS) operates in two healthcare-focused businesses: payment services for plasma donors and pharmaceutical patient-affordability programs, Chief Financial Officer Jeff Baker said during a company presentation. Baker described the company as both a payments and life sciences business
Paysign (PAYS) is an Incredible Growth Stock: 3 Reasons Why
Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Paysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock?
Paysign (PAYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Paysign (PAYS) Stock Gets Fair Value Boost After Q2 And Guidance Driven Analyst Lifts
The updated analyst work on Paysign now points to a higher implied fair value, with the modeled figure moving from US$10.45 to US$13.10. Bullish analysts link these higher targets to a stronger reaction to Paysign’s recent Q2 report, raised guidance and growing confidence in the company’s execution, including new pharma program wins. As you read on, you will see how these shifting targets fit into the broader narrative and what to watch as the story develops from here. Analyst Price Targets...
Are Business Services Stocks Lagging Paysign (PAYS) This Year?
Here is how Paysign, Inc. (PAYS) and Sezzle Inc. (SEZL) have performed compared to their sector so far this year.